EUVIMED · CrossrefJournal
Journal of Hepatology
ISSN 0168-8278 · Elsevier BV
Latest articles
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma
Regression of liver cirrhosis
MRI-based prediction of very early recurrence within 1 year after resection of HCC: An international cohort study
Reply to: “Agree to disagree; increasing the impact of recommendations formulated through Delphi methodology”
HbA1c trajectories and the risk of liver-related events in patients with type 2 diabetes mellitus
Fibrosis regression in chronic liver disease: The pathologist’s view
Baveno VIII – Advancing consensus in portal hypertension
Liver biopsy confirms precise and efficient correction of SERPINA1 after in vivo Base Editing in a Patient with Alpha-1 Antitrypsin Deficiency
Seladelpar for alkaline phosphatase normalization in primary biliary cholangitis: The IDEAL phase III randomized controlled trial
Senescence induces clonal failure of hepatocyte plasticity and reshapes regenerative lineages
Translocation of the environmental bacterium Aquitalea magnusonii promotes systemic inflammation and liver fibrosis in chronic liver disease
T cells and the bile duct: CD226-NECTIN2 as a druggable axis in immune-mediated cholangiopathy
Advances in the imaging of liver cancer
Surveillance of patients at risk of liver cancer: Expert opinions
Artificial intelligence and personalised medicine in liver cancer
Acute-on-chronic liver failure: A global multisociety consensus on definitions
Reply to: "beyond portal pressure: what does CIRI really predict?" and "can the CIRI model reliably predict cACLD decompensation for clinical adoption?"
Survival outcomes after liver transplantation in acute-on-chronic liver failure: A prospective study
Temporal assessment of spatial and single-cell transcriptomes identifies CD226-NECTIN2 T cell-cholangiocyte interaction in bile duct inflammation
Abnormal left ventricular mass as a prognostic marker for outcomes in infants and children with cirrhosis
Reply to: “Comment on surveillance of patients at risk of liver cancer: Expert opinions”
Reply to: “Statistical pitfalls in interpreting zero HCC risk and HBsAg clearance in the long-term PAGE-B cohort”
Dialling up success: Next generation treatments in primary biliary cholangitis
Cell-free DNA methylation for detection of early HCC: Promising signals, but not yet a surveillance test
Crosstalk along the gut–liver axis in liver disease: Clinical and mechanistic aspects
HBs proteins do not reveal their genomic origin
EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and post-treatment results from a phase III randomized trial
Fusobacterium nucleatum alleviates alcohol-associated liver disease through mannose-mediated elevation of Fbp1 and modulation of gut microbiota
Single-nucleus profiling reveals hepatocyte identity and immune features associated with corticosteroid response in severe alcohol-related hepatitis
Volumes
2026 · 4702025 · 2,5162024 · 2,4002023 · 2,4642022 · 2,2702021 · 5912020 · 2,2122019 · 2,1942018 · 2,2872017 · 2,2362016 · 2,1572015 · 2,1352014 · 2,0862013 · 1,9982012 · 2,0282011 · 1,9082010 · 1,6162009 · 1,5022008 · 1,4132007 · 1,1792006 · 1,1792005 · 1,1732004 · 1,1112003 · 1,1762002 · 1,3272001 · 2,0652000 · 1,1741999 · 4141998 · 1,0861997 · 4391996 · 2951995 · 3151994 · 1,0161993 · 3341992 · 2691991 · 9371990 · 6951989 · 6491988 · 5211987 · 584
EUVIMED